Navigation Links
Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
Date:11/8/2013

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO),  a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will host a conference call at 10:00 a.m. ET on Wednesday, November 13, 2013 to discuss the third quarter financial results and other business updates.  A question-and-answer session will follow managements' remarks. The Company will report third quarter 2013 results on Tuesday, November 12, 2013 after the close of the U.S. financial markets. 

To access the conference call and participate in the question-and-answer session, the number for domestic callers is (877) 870-4263 and for international callers (412) 317-0790. The conference call replay number is (877) 344-7529 or (412) 317-0088. The passcode for the replay is 10036729.

The audio webcast of the conference call will be available on the Discovery Labs website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. A replay of the audio webcast will be available after the call at the Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs' technology platforms include its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants.  Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

For more information, please visit the Company's website at www.discoverylabs.com.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
4. Discovery of a dark state could mean a brighter future for solar energy
5. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
6. AnaptysBio Announces New Strategic Antibody Discovery
7. Discovery opens door to low-cost negative refraction, new products and industries
8. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
9. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
10. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
11. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... ... the move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on 15 August ... create an improved user experience and incorporate a number of enhancements and new ...
(Date:9/17/2017)... Seoul (PRWEB) , ... September 17, 2017 , ... ... approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for ... vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in ...
(Date:9/14/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... company, will gather the most innovative minds in pharma and biotech at the ... is a two-day collaborative conference that brings together the world’s most progressive clinical ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... Lumbar Disc case in Australia. Dr. Steven Yang completed the procedure on a ... result of a degenerative lumbar disc at level L5-S1. The patient failed conservative ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):